Evaluating Bristol-Myers Squibb’s Valuation After Real-World Camzyos Study Results at European Cardiology Congress

Bristol-Myers Squibb (BMY) just made waves at the European Society of Cardiology Congress, unveiling new real-world data for Camzyos in symptomatic obstructive hypertrophic cardiomyopathy. The COLLIGO-HCM study confirms that Camzyos delivers meaningful improvements for patients across multiple countries and demographics. This aligns with past clinical trials and reinforces its place as a go-to treatment. For investors, these kinds of clinical milestones can often shift the narrative around a pharma company's long-term growth story, so it is worth taking a closer look at what this means moving forward. Despite the momentum from Camzyos and continued appearances at industry conferences, Bristol-Myers Squibb’s stock has seen mixed action. Over the past year the share price has barely budged, while longer-term returns remain under pressure. The company’s numbers show a slight positive return for the year, but its three-year and five-year performance trail the broader market. This raises questions about whether investor enthusiasm is starting to build around these product updates or if caution still dominates. With all this in play, the core question for investors comes down to valuation and whether the stock is being overlooked as future growth takes shape, or if recent gains have already been priced in. Is this the entry point you have been waiting for, or is the market a step ahead?

Most Popular Narrative: 28.1% Undervalued

According to the most widely discussed narrative, Bristol-Myers Squibb is currently trading at a steep discount to its estimated fair value, suggesting that the market may be missing something. The analysis points to the company being undervalued by more than 28 percent, based on a blend of projected earnings, revenue trends, and discounted cash flow.

Fourth Quarter 2024 Highlights:

• Total Revenues: $12.3 billion, an 8% increase from the same period in 2023.
• GAAP Earnings Per Share (EPS): $0.04, a significant decrease from $0.87 in Q4 2023.
• Non-GAAP EPS: $1.67, slightly down from $1.70 in Q4 2023.
• Growth Portfolio Revenues: $6.4 billion, a 21% increase, driven by strong demand for products like Eliquis.

Want to know what’s fueling this bold undervaluation? The narrative is built on growth acceleration in key revenue lines and dramatic shifts in future profitability. Think you can guess the hidden assumptions behind this discount? There is a specific financial lever that might surprise you. Discover what is driving the valuation.

Result: Fair Value of $65 (UNDERVALUED)

Have a read of the narrative in full and understand what's behind the forecasts.

However, caution is warranted, as future revenue growth and successful execution of cost-saving measures remain critical risks that could challenge the undervaluation thesis.

Find out about the key risks to this Bristol-Myers Squibb narrative.

Another View: What Does Our DCF Model Say?

Our SWS DCF model takes a different approach from earnings multiples, focusing on projected cash flows instead of profit numbers. This method also points to undervaluation. However, do these models see the same opportunity or miss the nuances?

Look into how the SWS DCF model arrives at its fair value.

Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out Bristol-Myers Squibb for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover undervalued stocks based on their cash flows. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity.

Build Your Own Bristol-Myers Squibb Narrative

If you have your own perspective or want to dig deeper, you can build your own Bristol-Myers Squibb narrative in just a few minutes. Do it your way.

A great starting point for your Bristol-Myers Squibb research is our analysis highlighting 3 key rewards and 3 important warning signs that could impact your investment decision.

Looking for More Investment Ideas?

Take your strategy further and uncover smart opportunities you might be missing. Start searching for overlooked winners and fresh market themes with these handpicked stock ideas:

• Tap into potential high flyers by targeting penny stocks with strong financials making waves with strong financial performance in unexpected corners of the market.
• Zero in on future tech leaders behind game-changing innovations in medicine using our selection of healthcare AI stocks reshaping how healthcare works.
• Put your capital to work with steady earners. Find companies offering generous yields above 3% by scanning dividend stocks with yields > 3% built for income-focused investors.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com